By Fineline Cube 
FUJIFILM Diosynth Biotechnologies (FDB), a leading global contract development and manufacturing organization (CDMO) specializing in biologics, vaccines, cell and gene therapies, and oncolytic viruses, has entered into a 10-year strategic agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The USD 3 billion contract designates FDB as Regeneron’s domestic manufacturing partner for commercial-scale production of biologic therapies in the United States.
Strategic Agreement Details
Under the terms of the agreement, FDB will utilize its new 1.6 million-square-foot biomanufacturing campus in Holly Springs, North Carolina, which is slated to begin operations in 2025. The collaboration includes capacity expansion through both existing infrastructure and planned facility upgrades. This strategic partnership is expected to create 1,400 new jobs by 2031 across bioprocessing, quality assurance, and engineering roles.-Fineline Info & Tech